Company news

Telix Pharmaceuticals Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Leadership changes including Darren Smith appointment as CFO

May 31, 2022

Illuccix Reimbursement Milestone and Launch Updates

May 29, 2022

Appendix 4C and Activities Report for March 2022 quarter

April 21, 2022

ProstACT TARGET Phase II Study Ethics Approval

April 11, 2022

Telix Enters Licence Agreement with Lilly for Olaratumab

April 10, 2022

Telix, GMS & Monash Awarded $23 million Federal Funding

April 4, 2022

Commercial Launch - Illuccix Now Available to Order in US

April 3, 2022

FDA Orphan Drug Designation for Bone Marrow Conditioning

March 29, 2022

Telix and Xiel Sign U.K. and Ireland Distribution Agreement

March 28, 2022

Development of Glioblastoma Therapy Program

March 22, 2022

Radiopharmaceutical Production Facility Buildout Commences

March 21, 2022

ZIRCON Phase 3 Imaging Study Completes Targets Enrolment

March 7, 2022

Cancellation of Share Purchase Plan

March 1, 2022

2021 Full Year Results Presentation

February 23, 2022

Commercial Distribution Agreement for Illuccix for Australia

February 15, 2022

Telix Granted Illuccix EU Regulatory Review Extension

February 6, 2022

Sydney Airport to be removed from the S&P/ASX 200 Index

February 3, 2022

1st Patient Dosed ProstACT Prostate Cancer Therapy Program

January 26, 2022

Appendix 4C and Activities Report for December 2021 Quarter

January 23, 2022

Capital Raise Presentation

January 23, 2022

Telix completes $175M placement and launches $25M SPP

January 23, 2022

Targeted Alpha Therapy for Bladder Cancer 1st patient dosed

December 20, 2021

FDA Approves Telix Prostate Cancer Imaging Product Illuccix

December 19, 2021

Illuccix EU Regulatory Submission Progress Update

December 9, 2021

NUCLIBER - Distribution Agreement for Illuccix in Spain

December 7, 2021

Illuccix Granted Use Authorisation in Brazil

November 30, 2021

Investor Presentation - November 2021

November 15, 2021

Australian TGA Approves Illuccix for Prostate Cancer Imaging

November 1, 2021

Activities Report and App 4C - September 2021 quarter

October 20, 2021

IPAX-1 Presentation at Congress of Neurological Surgeons

October 19, 2021

$12.1M R&D Tax Refund, Overseas Finding Increased to $139M

September 27, 2021

FDA Extends New Drug Application Review Period for Illuccix

September 22, 2021

FDA Approves Phase II Kidney Cancer Therapy Study

September 13, 2021

Telix and Radius sign Distribution Agreement for Italy

September 12, 2021

Results Presentation and Shareholder Update 1H 2021

August 18, 2021

App 4D and Report for Half-Year Ended 30 June 2021

August 18, 2021

Telix and Merck pan-cancer clinical collaboration

August 17, 2021

TLX66 in Phase II Academic Study of Pediatric Leukemia

August 16, 2021

Telix Seneffe Production Facility - Progress Update

July 29, 2021

App 4C and Activities Report for June 2021 Quarter

July 21, 2021

ZIRCON Phase 3 Renal Cancer Imaging Study - Progress Update

July 19, 2021

TLX101 for Glioblastoma Therapy - Clinical Trial Update

June 20, 2021

Update on FDA New Drug Application Review for Illuccix

June 16, 2021

US Co-Promotion with EZAG for Prostate Cancer Imaging

June 3, 2021

TLX66 Meets Study Objectives in Patients with AL Amyloidosis

May 24, 2021

German Distribution Agreement with Eckert and Ziegler

May 17, 2021

Phase III Prostate Cancer Therapy Clinical Trial Commences

May 9, 2021

Activities Report and App 4C for quarter ended 31 March 2021

April 21, 2021

Japanese Renal Cancer Imaging Trial Meets Study Objectives

April 20, 2021

Launch of International NOBLE Registry for SPECT Imaging

April 18, 2021

← Newer news releases · Older news releases →

Calls

Decks

The 5 newest of 57 decks. Every deck is listed under its year.